These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33644945)

  • 1. Significant decrease in delirium referrals after changing hypnotic from benzodiazepine to suvorexant.
    Tachibana M; Inada T; Ichida M; Kojima S; Arai T; Naito K; Ozaki N
    Psychogeriatrics; 2021 May; 21(3):324-332. PubMed ID: 33644945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort.
    Nishimura S; Nakao M
    J Med Econ; 2018 Jul; 21(7):698-703. PubMed ID: 29667471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits associated with switching from benzodiazepine hypnotics to suvorexant in patients with mild primary insomnia.
    Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K
    Asian J Psychiatr; 2017 Oct; 29():71-72. PubMed ID: 29061431
    [No Abstract]   [Full Text] [Related]  

  • 5. Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study.
    Masuyama T; Sanui M; Yoshida N; Iizuka Y; Ogi K; Yagihashi S; Nagatomo K; Sasabuchi Y; Lefor AK
    Psychogeriatrics; 2018 May; 18(3):209-215. PubMed ID: 29423967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suvorexant for Primary Insomnia in a Patient at High Risk for Hypnotic Dependence.
    Singh J; Kaur H; Yadav S; Krishnamurthy VB
    Prim Care Companion CNS Disord; 2022 Mar; 24(2):. PubMed ID: 35254738
    [No Abstract]   [Full Text] [Related]  

  • 7. Suvorexant: scientifically interesting, utility uncertain.
    Keks NA; Hope J; Keogh S
    Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder.
    Shigetsura Y; Imai S; Endo H; Shimizu Y; Ueda K; Murai T; Itohara K; Nakagawa S; Yonezawa A; Ikemi Y; Fukatsu S; Kitada N; Terada T; Nakagawa T; Matsubara K
    Clin Neuropharmacol; 2022 May-Jun 01; 45(3):52-60. PubMed ID: 35579484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Hypnotic Drug Use with Fall Incidents in Hospitalized Elderly Patients: A Case-Crossover Study.
    Torii H; Ando M; Tomita H; Kobaru T; Tanaka M; Fujimoto K; Shimizu R; Ikesue H; Okusada S; Hashida T; Kume N
    Biol Pharm Bull; 2020; 43(6):925-931. PubMed ID: 32475914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual effects of low dose of suvorexant, zolpidem, and ramelteon in healthy elderly subjects: A randomized double-blind study.
    Uemura SI; Imanishi A; Terui Y; Park I; Satake M; Han G; Shioya T; Kanbayashi T; Nishino S
    Neuropsychopharmacol Rep; 2022 Sep; 42(3):288-298. PubMed ID: 35748642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of suvorexant versus benzodiazepine receptor agonist sleep drugs in reducing the risk of hip fracture: Findings from a regional population-based cohort study.
    Yoshioka R; Yamamoto S; Nakatani E
    PLoS One; 2023; 18(4):e0284726. PubMed ID: 37093840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Standardization of Hypnotic Agents for Prevention of Falls: A Pharmacoeconomic Study].
    Saisyo A; Takasago M; Wakabayashi K; Akiyama M; Kouda K; Takasaki A; Matsunaga K; Ishida H; Kitahara T
    Yakugaku Zasshi; 2021; 141(7):971-978. PubMed ID: 34193657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suvorexant: something new for sleep?
    Reddy A; Puvvada SC; Kommisetti S; El-Mallakh RS; Lippmann S
    Acta Neuropsychiatr; 2015 Feb; 27(1):53-5. PubMed ID: 25397996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Preventive Effects of Suvorexant in Intensive Care Delirium: A Retrospective Cohort Study.
    Izuhara M; Izuhara HK; Tsuchie K; Araki T; Ito T; Sato K; Miura S; Otsuki K; Nagahama M; Hayashida M; Hashioka S; Wake R; Kimura T; Tsumoto S; Saito Y; Inagaki M
    J Clin Psychiatry; 2020 Oct; 81(6):. PubMed ID: 33027560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of suvorexant in the prevention of delirium during acute hospitalization: A systematic review.
    Adams AD; Pepin MJ; Brown JN
    J Crit Care; 2020 Oct; 59():1-5. PubMed ID: 32480359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.
    Vermeeren A; Vets E; Vuurman EF; Van Oers AC; Jongen S; Laethem T; Heirman I; Bautmans A; Palcza J; Li X; Troyer MD; Wrishko R; McCrea J; Sun H
    Psychopharmacology (Berl); 2016 Sep; 233(18):3341-51. PubMed ID: 27424295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suvorexant with or without ramelteon to prevent delirium: a systematic review and meta-analysis.
    Tian Y; Qin Z; Han Y
    Psychogeriatrics; 2022 Mar; 22(2):259-268. PubMed ID: 34881812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients.
    Kawada K; Ohta T; Tanaka K; Miyamura M; Tanaka S
    J Stroke Cerebrovasc Dis; 2019 Jan; 28(1):142-148. PubMed ID: 30322756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suvorexant-Induced Delirium.
    Yoshida K; Nakamura K; Yasui-Furukori N
    Prim Care Companion CNS Disord; 2018 Nov; 20(6):. PubMed ID: 30476370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.